Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 271-276

  Kim, Hee Joung ^a   Oh, Seo Young ^a   Kim, Wan Seop ^a   Kim, Sun Jong ^a   Yoo, Gwang Ha ^a   Kim, Won Dong ^a   Lee, Kye Young ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

EGFR mutation; Lung cancer; Pyrosequencing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; DNA EXTRACTION; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PYROSEQUENCING; SEX DIFFERENCE;

EID: 84869021787     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.950     Document Type: Article

References (29)

1. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
2. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): open label, randomized phase 3 trial. Lancet Oncol 11: 121-128, 2010.
3. Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-2449, 2008.
4. Rosell R, Viteri S, Molina MA, et al: Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 22: 112-120, 2010.
5. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 12: 3915-3921, 2006.
6. Kimura H, Fujiwara Y, Sone T, et al: High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 97: 642-648, 2006.
7. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al: A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3: 1224-1235, 2008.
8. Cohen V, Agulnik JS, Ang C, et al: Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer. Cancer 111: 4309-4317, 2010.
9. Kim HJ, Lee KY, Kim YC, et al: Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 75: 321-325, 2012.
10. Lee KY, Kim HJ, Kim SJ, et al: PNA-Mediated PCR Clamping for the detection of EGFR mutations in non-small cell lung cancer. Tuberc Respir Dis 69: 271-278, 2010.
11. Kim HJ, Kim WS, Shin KC, et al: Comparative analysis of peptide nucleic acid (PNA)-mediated real-time PCR clamping and DNA direct sequencing for EGFR mutation detection. Tuberc Respir Dis 70: 21-27, 2011.
12. Pao W and Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer, searching for the ideal method. Clin Cancer Res 13: 4954-4955, 2007.
13. Langaee T and Ronaghi M: Genetic variation analyses by pyrosequencing. Mutat Res 573: 96-102, 2005.
14. Ahmadian A, Ehn M and Hober S: Pyrosequencing: history, biochemistry and future. Clin Chim Acta 363: 83-94, 2006.
15. Dufort S, Richard MJ and Fraipont F: Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 391: 166-168, 2009.
16. Tsiatis AC, Norris-Kirby A, Rich RG, et al: Comparison of Sanger sequencing, pyrosequencing and melting curve analysis for the detection of KRAS mutations. J Mol Diagn 12: 425-432, 2010.
17. Kim SK, Kim DL, Han HS, et al: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17: 118-125, 2008.
18. Inoue A, Kobayashi K, Usui K, et al: First-line gefitinib for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27: 1394-1400, 2009.
19. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
20. Ettinger DS, Akerley W, Bepler G, et al: Non-small cell lung cancer. J Natl Compr Canc Netw 8: 740-801, 2010.
21. Pirker R, Herth FJ, Kerr KM, et al: Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5: 1706-1713, 2010.
22. Ronaghi M: Pyrosequencing sheds light on DNA sequencing. Genome Res 11: 3-11, 2001.
23. Ogino S, Kawasaki T, Brahmandam M, et al: Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7: 413-421, 2005.
24. Uhlmann K, Brinckmann A, Toliat MR, et al: Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 23: 4072-4079, 2002.
25. Tost J, Dunker J and Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques 35: 152-156, 2003.
26. Forbes SA, Bharma G, Bamford S, et al: The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: unit 10.11, 2008.
27. Rekhtman N, Brandt SM, Sigel CS, et al: Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGR and KRAS molecular testing. J Thor Oncol 6: 451-458, 2011.
28. Tokumo M, Toyooka S, Kiura K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005.
29. Shigematsu H, Lim L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.